What type of anti-cancer drugs does Erdafitinib/Bocco belong to?
Erdafitinib (Erdafitinib) is an oral small molecule tyrosine kinase inhibitor (TKI) anti-cancer drug that specifically targets tumors with abnormal fibroblast growth factor receptor (FGFR). FGFR is a type of receptor on the surface of tumor cells. Abnormal activation triggers cell proliferation, angiogenesis and metastasis signaling pathways, thereby promoting cancer development. As an FGFR inhibitor, erdafitinib blocks these abnormal signals and directly intervenes in the process of cancer cell proliferation and angiogenesis to achieve precise anti-tumor effects. This mechanism of action makes it different from traditional chemotherapy drugs and can act more selectively on molecularly abnormal tumor cells while reducing toxicity to normal tissues.

The clinical application of erdafitinib is mainly focused on patients with advanced bladder cancer and some solid tumors with FGFR gene abnormalities. Its targeted therapeutic properties make it particularly suitable for patient populations where standard treatments have failed or disease has progressed. Because it is a small molecule targeted drug, it can be used orally to facilitate long-term maintenance treatment. At the same time, it can be combined with clinical molecular testing results for individualized dose adjustment to ensure efficacy and safety.
In addition to bladder cancer, erdafitinib is also exploring the application potential of other FGFR-related tumors in some studies, such as cholangiocarcinoma and a few hematological tumors. By precisely targeting abnormal signaling pathways, it shows unique value in delaying disease progression, improving quality of life, and providing new treatment opportunities for patients.
In general, erdafitinib/BOC is a small molecule FGFR inhibitor targeted anti-cancer drug that achieves tumor control and disease remission by precisely intervening in abnormal signaling pathways of cancer cells. It is an important representative of modern precision anti-cancer treatment and also provides innovative treatment options for patients with tumors related to FGFR abnormalities.
References:https://www.balversa.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)